Wednesday, October 23, 2013 7:51:38 PM
Hsp90 is a longstanding target of anti-cancer drugs and it has been shown that down regulation of this protein strongly deactivates mutant p53 and upregulates normal p53.
There was actually a drug called Geldanamycin that did just that by inhibiting Hsp90, but unfortunately it had the draw back of liver toxicity. Certain analogues of the drug were being studied as late as 2010 by Bristol-Myers Squibb and studies may even be ongoing - someone contested the end of the trials on wikipedia.
"GA downregulated overexpressed mutant p53 protein (an oncogene) and upregulated wild-type (wt) p53 (a tumour suppressor). The upregulation of wt p53 by GA was independent of ATM and was accompanied by downregulation of Akt and the active form of MDM2, indicating a possible mechanism. GA also produced a p53/ATM-independent increase in the levels of p21-a potent inducer of cell-cycle arrest."
So contrary to what some on here have indicated K does not reactivate mutant p53, but actually promotes its destruction allowing it to be replaced with the functional wild type protein (which is generally ihibited by the very presence of the mutant p53).
Another interesting note is that Hsp90 has been linked to Alzheimer's disease (per the below) and down regulation has been linked to inhibiting the formation of tau (the protein responsible for Alzheimer's) so there is that implication if K can cross the blood brain barrier
"Consistent with previous research on Hsp90 clients in cancer, we provide evidence that a loss of HDAC6 activity augments the efficacy of an Hsp90 inhibitor and drives client degradation, in this case tau."
In summary, it appears that indeed the key to K's efficacy is Hsp90 inhibition via HDAC6 and HDAC2 inhibition. This is an insight that personally I did not have despite having read those posters numerous times. Thank you Orion for helping me attain this clarity.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM